RxDoctor Payments Data

Matthew Kaw, MD

Internal Medicine · El Monte, CANPI 1821044819

Payments from drug & device makers

$2,623in general payments, 2019–2025

Across 172 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$707
  • Amgen$235
  • Pfizer$218
  • Lilly USA, LLC$216
  • Novo Nordisk$163
  • AbbVie$162
  • plus $922 from 16 others

What the payments were for

  • Food & beverage$2,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,623 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$158,470
Medicare patients
266
Services billed
2,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin299$247,427
OzempicSemaglutide157$153,372
JanuviaSitagliptin Phosphate108$80,025
JanumetSitagliptin Phos/Metformin Hcl82$67,586
EliquisApixaban72$56,109
LinzessLinaclotide87$54,548
XareltoRivaroxaban46$40,492
ProliaDenosumab16$27,348
TrulicityDulaglutide25$23,169
Breo ElliptaFluticasone/Vilanterol53$21,390
RybelsusSemaglutide17$15,410
Janumet XrSitagliptin Phos/Metformin Hcl18$11,743
Diclofenac Sodium288$11,005
FarxigaDapagliflozin Propanediol15$10,199
Atrovent HfaIpratropium Bromide23$9,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Jentadueto$78$255,027314 claims
Novo NordiskOzempic, Rybelsus$163$168,783174 claims
MerckJanuvia, Janumet, Janumet Xr, Belsomra$120$165,595222 claims
PfizerEliquis$218$56,10972 claims
AbbVieLinzess$162$54,54887 claims
Johnson & JohnsonXarelto$707$40,49246 claims
AmgenProlia$235$27,34816 claims
Lilly USA, LLCTrulicity$216$23,16925 claims
GSKBreo Ellipta$18$21,39053 claims
AstraZenecaFarxiga$66$10,19915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in El Monte

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →